Research and Markets: Autistic Disorder Pipeline Assessment & Market Forecasts to 2017 - The Global Autistic Disorder Therapeutics Market was Valued at $331m in 2009

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/14b758/autistic_disorder) has announced the addition of GlobalData 's new report "Autistic Disorder - Pipeline Assessment and Market Forecasts to 2017" to their offering.

“Autistic Disorder - Pipeline Assessment and Market Forecasts to 2017”

Autistic Disorder - Pipeline Assessment and Market Forecasts to 2017 is an essential source of information and analysis on the global autism market. The report identifies the key trends shaping and driving the global autism market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global autism sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by a team of industry experts.

The Autistic Disorder Market is Forecast to Show Increased Growth until 2016

The authors have estimated the global autistic disorder therapeutics market to be valued at $331m in 2009. It is expected to grow to $765m with a compound annual growth rate (CAGR) of 11.05% by 2017. This growth is primarily attributed to the high increase in prevalence and also the rapid increase in public awareness about the condition. There is a high unmet need which is largely driven by the availability of only a few approved drugs like Abilify and Risperidone that are moderately successful in terms of safety and efficacy profile

Steady Increase in Disease Population to Boost the Present Market

The prevalence rate for autistic disorder globally was identified at 0.60% and this accounted for approximately 4.3 million people. Between 2009 and 2017 it is expected to increase from 4.3 million to seven million. Autistic disorder is commonly diagnosed between the ages of one and eight years. A significant increase in autistic disorder incidence has occurred over the past 10 years, especially in the new born population. Hence it is clear that the number of autistic spectrum disorder (ASD) patients seeking treatment in the next five to 10 years will result in an increased usage of therapeutics drugs which in turn will drive the ASD therapeutics market.

Only Two Products Approved for Treatment

The global autistic disorder market is dependent on only two drugs Risperidone and Abilify approved by the US Food and Drug Administration (FDA). Most of patients are prescribed anti-depressant or anti-psychotic drugs to treat the symptoms related to autistic disorder. The patent expiry of marketed products such as Risperidone by 2009 allowed the entry of generic products at cheaper prices reducing the market growth as well as the market size.

Scope:

The report provides information on the key drivers and challenges of the Autistic Disorder market. Its scope includes:
Annualized global Autistic Disorder market revenues data from 2001 to 2009, forecast for eight years to 2017.
Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as noradrenaline reuptake inhibitors, adrenergic uptake inhibitors, enzyme replacement therapy, dopamine agents, chelating agents and Gamma-amino butyric acid type B (GABA-B) receptor agonist
Analysis of the current and future competition in the global Autistic Disorder market. Key market players covered are Bristol-Myers Sqibb, Cellceutix Corporation, Seaside Therapeutics, Curemark LLC, Neuropharm Group and EilyLily.
Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Autistic Disorder therapeutics market.

Reasons to buy:

The report will enhance your decision making capability. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global Autistic Disorder market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Autistic Disorder market in future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Whats the next big thing in the global Autistic Disorder market landscape? - Identify, understand and capitalize.

Key Topics Covered:

1 Table of contents

2 Autistic Disorder Market: Introduction

3 Autistic Disorder Market: Market Characterization

4 Autistic Disorder Market: Competitive Assessment

5 Autistic Disorder Market: Pipeline Assessment

6 Autistic Disorder Market: Implications for Future Market Competition

7 Autistic Disorder Market: Future Players in the Autistic Disorder Market

8 Autistic Disorder Market: Appendix

Companies Mentioned: